T. Kopadze, M. Döbert, V. Leussink
Mar 1, 2009
Citations
2
Influential Citations
44
Citations
Journal
European Journal of Neurology
Abstract
Background: Damage of the blood–brain barrier and the migration of immunocompetent cells into the CNS represent key events in the immunopathogenesis of multiple sclerosis (MS). Cladribine is an immunosuppressive drug currently investigated in a phase‐III clinical trial for relapsing–remitting MS. However, its precise mode of action remains elusive so far.